Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

ClinicalTrials.gov ID: NCT00016341

Public ClinicalTrials.gov record NCT00016341. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the absorption of estrogen. It is not yet known whether chemotherapy is more effective than hormone therapy in treating endometrial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with that of hormone therapy in treating patients who have recurrent, stage III, or stage IV endometrial cancer.

Study identification

NCT ID
NCT00016341
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gynecologic Oncology Group
Network
Enrollment
Not listed

Conditions and interventions

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2001 (Type not available)
Primary completion
Oct 2003 (Actual)
Completion
Not listed
Last update posted
Apr 11, 2013

Started 2001

United States locations

U.S. sites
49
U.S. states
26
U.S. cities
44
Facility City State ZIP Site status
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama 35294-3300 —
Jonsson Comprehensive Cancer Center, UCLA Los Angeles California 90095-1781 —
Community Hospital of Los Gatos Los Gatos California 95032 —
Chao Family Comprehensive Cancer Center Orange California 92868 —
University of Colorado Cancer Center Denver Colorado 80010 —
Walter Reed Army Medical Center Washington D.C. District of Columbia 20307-5000 —
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612-9497 —
Rush-Presbyterian-St. Luke's Medical Center Chicago Illinois 60612 —
University of Chicago Cancer Research Center Chicago Illinois 60637-1470 —
Indiana University Cancer Center Indianapolis Indiana 46202-5289 —
Holden Comprehensive Cancer Center at The University of Iowa Iowa City Iowa 52242-1009 —
Albert B. Chandler Medical Center, University of Kentucky Lexington Kentucky 40536-0084 —
Tufts University School of Medicine Boston Massachusetts 02111 —
University of Massachusetts Memorial Medical Center Worcester Massachusetts 01655 —
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201-1379 —
University of Minnesota Cancer Center Minneapolis Minnesota 55455 —
Mayo Clinic Cancer Center Rochester Minnesota 55905 —
University of Mississippi Medical Center Jackson Mississippi 39216-4505 —
Ellis Fischel Cancer Center - Columbia Columbia Missouri 65203 —
Washington University School of Medicine St Louis Missouri 63110 —
Cooper Hospital/University Medical Center Camden New Jersey 08103 —
Cancer Center of Albany Medical Center Albany New York 12208 —
State University of New York Health Science Center at Brooklyn Brooklyn New York 11203 —
Roswell Park Cancer Institute Buffalo New York 14263-0001 —
Schneider Children's Hospital at North Shore Manhasset New York 11030 —
Memorial Sloan-Kettering Cancer Center New York New York 10021 —
State University of New York Health Sciences Center - Stony Brook Stony Brook New York 11790-7775 —
Lineberger Comprehensive Cancer Center, UNC Chapel Hill North Carolina 27599-7295 —
Duke Comprehensive Cancer Center Durham North Carolina 27710 —
Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina 27157-1082 —
Barrett Cancer Center, The University Hospital Cincinnati Ohio 45267-0502 —
Ireland Cancer Center Cleveland Ohio 44106-5065 —
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195 —
Arthur G. James Cancer Hospital - Ohio State University Columbus Ohio 43210-1240 —
University of Oklahoma College of Medicine Oklahoma City Oklahoma 73190 —
Abington Memorial Hospital Abington Pennsylvania 19001 —
Milton S. Hershey Medical Center Hershey Pennsylvania 17033-0850 —
University of Pennsylvania Cancer Center Philadelphia Pennsylvania 19104-4283 —
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia Philadelphia Pennsylvania 19107-5541 —
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 —
Medical University of South Carolina Charleston South Carolina 29425-0721 —
Brookview Research, Inc. Nashville Tennessee 37203 —
Simmons Cancer Center - Dallas Dallas Texas 75235-9154 —
M.D. Anderson CCOP Research Base Houston Texas 77030-4009 —
University of Texas - MD Anderson Cancer Center Houston Texas 77030-4009 —
Fletcher Allen Health Care - Medical Center Campus Burlington Vermont 05401 —
Cancer Center at the University of Virginia Charlottesville Virginia 22908 —
Fred Hutchinson Cancer Research Center Seattle Washington 98109-1024 —
Tacoma General Hospital Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00016341, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 11, 2013 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00016341 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →